{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:30Z","timestamp":1790957550306,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.intimp.2019.106081","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T19:21:15Z","timestamp":1576005675000},"page":"106081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["ACE inhibitor-mediated angioedema"],"prefix":"10.1016","volume":"78","author":[{"given":"Vincenzo","family":"Montinaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0005","doi-asserted-by":"crossref","first-page":"e0119292","DOI":"10.1371\/journal.pone.0119292","article-title":"National trends in the ambulatory treatment of hypertension in the United States, 1997\u20132012","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0010","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink","volume":"82","author":"Mahmoudpour","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2019.106081_b0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.clinthera.2007.09.019","article-title":"Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?","volume":"29","author":"Weir","year":"2007","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2019.106081_b0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjcard.2016.07.074","article-title":"Meta-analysis of randomized trials on the efficacy and safety of angiotensin-converting enzyme inhibitors in patients \u226565 years of age","volume":"118","author":"Bavishi","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.intimp.2019.106081_b0025","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: a UK population-based study","volume":"84","author":"Mahmoudpour","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2500\/aap.2013.34.3618","article-title":"Adverse drug effects and angioedema hospitalizations in the United States from 2000 to 2009","volume":"34","author":"Lin","year":"2013","journal-title":"Allergy Asthma Proc."},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10875-015-0228-3","article-title":"Angioedema triggered by medication blocking the renin\/angiotensin system: retrospective study using the french national pharmacovigilance database","volume":"36","author":"Faisant","year":"2016","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0040","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.anai.2014.09.003","article-title":"Angioedema deaths in the United States, 1979\u20132010","volume":"113","author":"Kim","year":"2014","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"20","key":"10.1016\/j.intimp.2019.106081_b0045","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0050","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record","volume":"5","author":"Banerji","year":"2017","journal-title":"J. Allergy Clin. Immunol Pract."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0055","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/joim.12867","article-title":"Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors \u2013 a nationwide registry-based cohort study","volume":"285","author":"Rasmussen","year":"2019","journal-title":"J. Intern. Med."},{"issue":"11","key":"10.1016\/j.intimp.2019.106081_b0060","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/lary.24777","article-title":"Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors","volume":"124","author":"Loftus","year":"2014","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/joim.12304","article-title":"Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients","volume":"277","author":"Mansi","year":"2015","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"issue":"14","key":"10.1016\/j.intimp.2019.106081_b0075","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0080","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.intimp.2019.106081_b0085","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pds.4260","article-title":"Antihypertensive drug associated angioedema: effect modification by race\/ethnicity","volume":"26","author":"Reichman","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40256-017-0256-x","article-title":"A database cohort study to assess the risk of angioedema among patients with heart failure initiating angiotensin-converting enzyme inhibitors in the USA","volume":"18","author":"Do","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"8","key":"10.1016\/j.intimp.2019.106081_b0095","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/lary.25821","article-title":"Case-control study evaluating competing risk factors for angioedema in a high-risk population","volume":"126","author":"Kamil","year":"2016","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","article-title":"Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema","volume":"51","author":"Byrd","year":"2008","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.intimp.2019.106081_b0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1060028016682251","article-title":"Comparison of clinical factors between patients with angiotensin-converting enzyme inhibitor-induced angioedema and cough","volume":"51","author":"Hallberg","year":"2017","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.intimp.2019.106081_b0110","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"Duerr","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.intimp.2019.106081_b0115","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1398-9995.2010.02398.x","article-title":"Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use","volume":"65","author":"Byrd","year":"2010","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2007.04.012","article-title":"Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema","volume":"120","author":"Byrd","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.intimp.2019.106081_b0130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archinte.164.8.910","article-title":"Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment","volume":"164","author":"Cicardi","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.intimp.2019.106081_b0135","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension","volume":"12","author":"White","year":"2010","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0140","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40256-017-0242-3","article-title":"Angioedema among hypertensive patients treated with aliskiren or other antihypertensive medications in the United States","volume":"17","author":"Schlienger","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"9230","key":"10.1016\/j.intimp.2019.106081_b0145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","article-title":"Vasopeptidase inhibition and angio-oedema","volume":"356","author":"Messerli","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jcpt.12363","article-title":"Neprilysin inhibition with sacubitril\/valsartan in the treatment of heart failure: mortality bang for your buck","volume":"41","author":"Ansara","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"issue":"264","key":"10.1016\/j.intimp.2019.106081_b0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","article-title":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study","volume":"1","author":"Shi","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.intimp.2019.106081_b0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"Banerji","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0165","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.otohns.2007.08.012","article-title":"Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"137","author":"Grant","year":"2007","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"11","key":"10.1016\/j.intimp.2019.106081_b0170","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J. Hypertens."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0175","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.amjcard.2011.11.014","article-title":"Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic","volume":"109","author":"Roberts","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2500\/aap.2013.34.3664","article-title":"Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"34","author":"Gang","year":"2013","journal-title":"Allergy Asthma Proc."},{"issue":"45","key":"10.1016\/j.intimp.2019.106081_b0185","doi-asserted-by":"crossref","first-page":"e1939","DOI":"10.1097\/MD.0000000000001939","article-title":"Angioedema related to angiotensin-converting enzyme inhibitors: attack severity, treatment, and hospital admission in a prospective multicenter study","volume":"94","author":"Javaud","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0190","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1056\/NEJMicm1014034","article-title":"Images in clinical medicine Angioedema","volume":"365","author":"Bramante","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2019.106081_b0195","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/MCG.0b013e318299c69d","article-title":"Angiotensin converting enzyme inhibitor-induced gastrointestinal angioedema: a case series and literature review","volume":"47","author":"Benson","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0897190017690641","article-title":"ACE inhibitor-induced angioedema of the small bowel: a case report and review of the literature","volume":"31","author":"Wilin","year":"2018","journal-title":"J. Pharm. Pract."},{"issue":"8","key":"10.1016\/j.intimp.2019.106081_b0205","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM200208223470820","article-title":"Bradykinin-mediated angioedema","volume":"347","author":"Nussberger","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"9117","key":"10.1016\/j.intimp.2019.106081_b0210","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0215","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2019.106081_b0220","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2017.03.003","article-title":"Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema","volume":"5","author":"Sinert","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2019.106081_b0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0162-3109(99)00107-1","article-title":"Angioedema due to angiotensin-converting enzyme inhibitors","volume":"44","author":"Agostoni","year":"1999","journal-title":"Immunopharmacology"},{"issue":"4","key":"10.1016\/j.intimp.2019.106081_b0235","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaip.2018.04.022","article-title":"Angioedema due to bradykinin dysregulation","volume":"6","author":"Cicardi","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molmed.2008.12.001","article-title":"C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress","volume":"15","author":"Cugno","year":"2009","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0245","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jch.12104","article-title":"Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans","volume":"15","author":"Moholisa","year":"2013","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0250","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/HYPERTENSIONAHA.107.102574","article-title":"Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition","volume":"51","author":"Van Guilder","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0255","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"Stone","year":"2017","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.intimp.2019.106081_b0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","article-title":"The kallikrein-kinin system: current and future pharmacological targets","volume":"99","author":"Moreau","year":"2005","journal-title":"J. Pharmacol. Sci."},{"issue":"9323","key":"10.1016\/j.intimp.2019.106081_b0265","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","article-title":"Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors","volume":"359","author":"Adam","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2019.106081_b0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1086\/496899","article-title":"A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors","volume":"77","author":"Duan","year":"2005","journal-title":"Am. J. Hum. Genet."},{"issue":"9","key":"10.1016\/j.intimp.2019.106081_b0275","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","article-title":"Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"20","author":"Woodard-Grice","year":"2010","journal-title":"Pharmacogenet. Genom."},{"issue":"11","key":"10.1016\/j.intimp.2019.106081_b0280","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/humu.21579","article-title":"A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema","volume":"32","author":"Cilia La Corte","year":"2011","journal-title":"Hum. Mutat."},{"issue":"9","key":"10.1016\/j.intimp.2019.106081_b0285","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"23","author":"Pare","year":"2013","journal-title":"Pharmacogenet. Genom."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0290","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0735-1097(98)00441-0","article-title":"Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs","volume":"32","author":"Jalowy","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0295","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/01.HYP.0000064942.77814.26","article-title":"AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin\/B2-receptor-dependent mechanism","volume":"41","author":"Hornig","year":"2003","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0305","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1523-1755.2000.00877.x","article-title":"The angiotensin type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice","volume":"57","author":"Hunley","year":"2000","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.iac.2016.08.011","article-title":"The angiotensin-converting-enzyme-induced angioedema","volume":"37","author":"Bas","year":"2017","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"4","key":"10.1016\/j.intimp.2019.106081_b0315","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jemermed.2012.07.055","article-title":"Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor-induced angioedema","volume":"44","author":"Hassen","year":"2013","journal-title":"J. Emerg. Med."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0320","doi-asserted-by":"crossref","first-page":"E198","DOI":"10.1002\/lary.25113","article-title":"Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema","volume":"125","author":"Greve","year":"2015","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.intimp.2019.106081_b0325","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.annemergmed.2014.07.014","article-title":"Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial","volume":"65","author":"Lewis","year":"2015","journal-title":"Ann. Emerg. Med."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0330","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anai.2014.12.007","article-title":"Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department","volume":"114","author":"Bernstein","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0335","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2500\/aap.2015.36.3892","article-title":"Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey","volume":"36","author":"Longhurst","year":"2015","journal-title":"Allergy Asthma Proc."},{"issue":"6","key":"10.1016\/j.intimp.2019.106081_b0340","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/all.13103","article-title":"Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice","volume":"72","author":"Zanichelli","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0345","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-016-8585-0","article-title":"Efficacy of treatment of non-hereditary angioedema","volume":"54","author":"van den Elzen","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0350","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.annemergmed.2010.03.032","article-title":"Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series","volume":"56","author":"Bas","year":"2010","journal-title":"Ann. Emerg. Med."},{"issue":"3","key":"10.1016\/j.intimp.2019.106081_b0355","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11739-015-1205-9","article-title":"Treatment of ACEI-related angioedema with icatibant: a case series","volume":"10","author":"Bova","year":"2015","journal-title":"Intern. Emerg. Med."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0360","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2019.106081_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.09.051","article-title":"Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema","volume":"140","author":"Straka","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106081_b0370","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","article-title":"HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group)","volume":"69","author":"Cicardi","year":"2014","journal-title":"Allergy"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919318296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919318296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:19:39Z","timestamp":1761585579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919318296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":74,"alternative-id":["S1567576919318296"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106081","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACE inhibitor-mediated angioedema","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106081"}}